{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The number of patients without an unequivocal increase in tumor size or the appearance of new lesions by MRI","groups":[{"description":"Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.\n\nrituximab: Given IV\n\nyttrium Y 90 ibritumomab tiuxetan: Given IV","id":"OG000","title":"Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan"}],"populationDescription":"Only one patient registered. No patient data analyzed","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Progression Free Survival","type":"SECONDARY"}